Global Preventable Vaccines Market Overview:
Global Preventable Vaccines Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Preventable Vaccines Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Preventable Vaccines involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Preventable Vaccines Market:
The Preventable Vaccines Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Preventable Vaccines Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Preventable Vaccines Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Preventable Vaccines market has been segmented into:
Live / Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines
Other Vaccine Types
By Application, Preventable Vaccines market has been segmented into:
Poliovirus Disease
Pneumococcal Disease
Hepatitis Disease
Influenza Disease
Measles & Rubella Disease
Other Disease Types
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Preventable Vaccines market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Preventable Vaccines market.
Top Key Players Covered in Preventable Vaccines market are:
AstraZeneca PLC
Bharat Biotech International Ltd.
Boehringer Ingelheim International GmbH
Daiichi Sankyo Co. Ltd.
Emergent BioSolutions Inc.
GSK Plc
Johnson & Johnson Services Inc.
Merck & Co. Inc.
Novartis AG
Novavax Inc.
Pfizer Inc.
Roche CustomBiotech
Sanofi SA
Serum Institute of India Pvt. Ltd.
Takeda Pharmaceutical Co. Ltd.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Preventable Vaccines Market Type
4.1 Preventable Vaccines Market Snapshot and Growth Engine
4.2 Preventable Vaccines Market Overview
4.3 Live / Attenuated Vaccines
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Live / Attenuated Vaccines: Geographic Segmentation Analysis
4.4 Inactivated Vaccines
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Inactivated Vaccines: Geographic Segmentation Analysis
4.5 Subunit Vaccines
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Subunit Vaccines: Geographic Segmentation Analysis
4.6 Toxoid Vaccines
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Toxoid Vaccines: Geographic Segmentation Analysis
4.7 Other Vaccine Types
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Other Vaccine Types: Geographic Segmentation Analysis
Chapter 5: Preventable Vaccines Market Application
5.1 Preventable Vaccines Market Snapshot and Growth Engine
5.2 Preventable Vaccines Market Overview
5.3 Poliovirus Disease
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Poliovirus Disease: Geographic Segmentation Analysis
5.4 Pneumococcal Disease
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Pneumococcal Disease: Geographic Segmentation Analysis
5.5 Hepatitis Disease
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Hepatitis Disease: Geographic Segmentation Analysis
5.6 Influenza Disease
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Influenza Disease: Geographic Segmentation Analysis
5.7 Measles & Rubella Disease
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Measles & Rubella Disease: Geographic Segmentation Analysis
5.8 Other Disease Types
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Other Disease Types: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Preventable Vaccines Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ASTRAZENECA PLC; BHARAT BIOTECH INTERNATIONAL LTD.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; DAIICHI SANKYO CO.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 LTD.; EMERGENT BIOSOLUTIONS
6.4 INC.; GSK PLC; JOHNSON & JOHNSON SERVICES
6.5 INC.; MERCK & CO.
6.6 INC.; NOVARTIS AG; NOVAVAX
6.7 INC.; PFIZER
6.8 INC.; ROCHE CUSTOMBIOTECH; SANOFI SA; SERUM INSTITUTE OF INDIA PVT.
6.9 LTD.; TAKEDA PHARMACEUTICAL CO.
6.10 LTD.
Chapter 7: Global Preventable Vaccines Market By Region
7.1 Overview
7.2. North America Preventable Vaccines Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Live / Attenuated Vaccines
7.2.2.2 Inactivated Vaccines
7.2.2.3 Subunit Vaccines
7.2.2.4 Toxoid Vaccines
7.2.2.5 Other Vaccine Types
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Poliovirus Disease
7.2.3.2 Pneumococcal Disease
7.2.3.3 Hepatitis Disease
7.2.3.4 Influenza Disease
7.2.3.5 Measles & Rubella Disease
7.2.3.6 Other Disease Types
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Preventable Vaccines Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Live / Attenuated Vaccines
7.3.2.2 Inactivated Vaccines
7.3.2.3 Subunit Vaccines
7.3.2.4 Toxoid Vaccines
7.3.2.5 Other Vaccine Types
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Poliovirus Disease
7.3.3.2 Pneumococcal Disease
7.3.3.3 Hepatitis Disease
7.3.3.4 Influenza Disease
7.3.3.5 Measles & Rubella Disease
7.3.3.6 Other Disease Types
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Preventable Vaccines Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Live / Attenuated Vaccines
7.4.2.2 Inactivated Vaccines
7.4.2.3 Subunit Vaccines
7.4.2.4 Toxoid Vaccines
7.4.2.5 Other Vaccine Types
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Poliovirus Disease
7.4.3.2 Pneumococcal Disease
7.4.3.3 Hepatitis Disease
7.4.3.4 Influenza Disease
7.4.3.5 Measles & Rubella Disease
7.4.3.6 Other Disease Types
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Preventable Vaccines Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Live / Attenuated Vaccines
7.5.2.2 Inactivated Vaccines
7.5.2.3 Subunit Vaccines
7.5.2.4 Toxoid Vaccines
7.5.2.5 Other Vaccine Types
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Poliovirus Disease
7.5.3.2 Pneumococcal Disease
7.5.3.3 Hepatitis Disease
7.5.3.4 Influenza Disease
7.5.3.5 Measles & Rubella Disease
7.5.3.6 Other Disease Types
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Preventable Vaccines Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Live / Attenuated Vaccines
7.6.2.2 Inactivated Vaccines
7.6.2.3 Subunit Vaccines
7.6.2.4 Toxoid Vaccines
7.6.2.5 Other Vaccine Types
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Poliovirus Disease
7.6.3.2 Pneumococcal Disease
7.6.3.3 Hepatitis Disease
7.6.3.4 Influenza Disease
7.6.3.5 Measles & Rubella Disease
7.6.3.6 Other Disease Types
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Preventable Vaccines Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Live / Attenuated Vaccines
7.7.2.2 Inactivated Vaccines
7.7.2.3 Subunit Vaccines
7.7.2.4 Toxoid Vaccines
7.7.2.5 Other Vaccine Types
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Poliovirus Disease
7.7.3.2 Pneumococcal Disease
7.7.3.3 Hepatitis Disease
7.7.3.4 Influenza Disease
7.7.3.5 Measles & Rubella Disease
7.7.3.6 Other Disease Types
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Preventable Vaccines Scope:
|
Report Data
|
Preventable Vaccines Market
|
|
Preventable Vaccines Market Size in 2025
|
USD XX million
|
|
Preventable Vaccines CAGR 2025 - 2032
|
XX%
|
|
Preventable Vaccines Base Year
|
2024
|
|
Preventable Vaccines Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
AstraZeneca PLC, Bharat Biotech International Ltd., Boehringer Ingelheim International GmbH, Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., GSK Plc, Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Novavax Inc., Pfizer Inc., Roche CustomBiotech, Sanofi SA, Serum Institute of India Pvt. Ltd., Takeda Pharmaceutical Co. Ltd..
|
|
Key Segments
|
By Type
Live / Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
Toxoid Vaccines
Other Vaccine Types
By Applications
Poliovirus Disease
Pneumococcal Disease
Hepatitis Disease
Influenza Disease
Measles & Rubella Disease
Other Disease Types
|
